6296-01-1 Usage
Uses
Used in Bodybuilding and Athletic Communities:
(6alpha,11beta,17beta)-11,17-dihydroxy-6,17-dimethylandrost-4-en-3-one is used as a prohormone for enhancing muscle growth and increasing strength. Its effects are believed to be similar to those of testosterone, making it a sought-after substance for individuals looking to improve their physical performance and physique.
However, it is important to note that due to its potential for abuse and adverse health effects, (6alpha,11beta,17beta)-11,17-dihydroxy-6,17-dimethylandrost-4-en-3-one is categorized as a controlled substance in some countries. As a result, its use may be subject to legal restrictions and regulations depending on the jurisdiction.
Check Digit Verification of cas no
The CAS Registry Mumber 6296-01-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,2,9 and 6 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 6296-01:
(6*6)+(5*2)+(4*9)+(3*6)+(2*0)+(1*1)=101
101 % 10 = 1
So 6296-01-1 is a valid CAS Registry Number.
6296-01-1Relevant academic research and scientific papers
ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT
-
, (2008/06/13)
The present invention relates to methods of providing male contraception using a specified androgen without the need of a separate sterilizing agent. The invention also describes methods for non-contraceptive androgen replacement and devices useful for carrying out both processes.
TRANSDERMAL ADMINISTRATION OF MENT
-
, (2008/06/13)
The present invention relates to transdermal dosage forms for delivery of androgens.
Method for androgen supplementation
-
, (2008/06/13)
A particular group of androgens is not metabolized to their 5α-reduced form in the prostate and other tissues. Thus, administration of these compounds--testosterone derivatives with a non-hydrogen substituent in the 6α or 7α position--allows one to provide androgen supplementation therapy without stimulating abnormal prostate growth. A preferred compound for use in the invention is 7α-methyl-19-nortestosterone.
